key: cord-0722676-jb582xpd authors: Naghashpour, Mahshid; Ghiassian, Hamid; Mobarak, Sara; Adelipour, Maryam; Piri, Maghsud; Seyedtabib, Maryam; Golabi, Sahar title: Profiling serum levels of glutathione reductase and interleukin‐10 in positive and negative‐PCR COVID‐19 outpatients: A comparative study from southwestern Iran date: 2021-11-27 journal: J Med Virol DOI: 10.1002/jmv.27464 sha: 70df68e264092ae0838988538525fbff8e5e053d doc_id: 722676 cord_uid: jb582xpd Since the outbreak of COVID‐19 in China, it has rapidly spread across many other countries. We evaluated antioxidant defense systems and inflammatory status related to the SARS‐CoV2 infection in a population from southwestern Iran. Comorbidities and clinical symptoms of 104 subjects (comprising negative and positive‐PCR COVID‐19 outpatients) were assessed. Serum concentrations of glutathione reductase (GR) and interleukin‐10 (IL‐10) were measured using ELISA. In the positive‐PCR group, follow‐ups on clinical symptoms were carried out for 28 days at 7‐day intervals. In the positive‐PCR group, hypertension, diabetes, liver disease, chronic heart disease, and chronic kidney disease were the most common comorbidities. In the general category of symptoms, we found a significant difference between negative and positive‐PCR groups, except regarding runny noses. In the pulmonary category, there was a significant difference between the two groups except in terms of chest pain. We also determined a significant difference in neurologic symptoms, except for ear pain, between negative and positive‐PCR groups. We also found significantly lower levels of GR but higher levels of IL‐10 in the positive‐PCR group (p = 0.000 for both). In the positive‐PCR group, serum levels of IL‐10 (odds ratio = 0.914, p = 0.012) decreased the chances of neurological symptoms occurring over time. The antioxidant defense systems of positive‐PCR outpatients failed as demonstrated by a reduction in the serum levels of GR. We also indicated a dysregulation in the immune response against COVID‐19, characterized by changes in serum IL‐10 levels. pathophysiological mechanisms of COVID-19 infection that may be useful to establish more efficient management protocols. 4 Human COVID-19 is divided into low and highly pathogenic species. However, the infection caused by this virus is not necessarily followed by recognizable symptoms. The low pathogenic infects the upper respiratory tract and causes mild respiratory problems such as colds. The highly pathogenic form causes more severe problems, such as acute respiratory syndrome, by infecting the lower airways. 5 For laboratory diagnosis of the virus, the virus's RNA can be detected using RT-PCR from samples of the upper respiratory tract, the lower respiratory tract, and blood plasma. This test is currently the gold standard for diagnosing the virus. 6, 7 The SARS-CoV2 receptor is an angiotensin-converting enzyme 2 (ACE2) that is expressed by almost all human organs. 3 ACE2 is a protease that, along with the angiotensin-converting Reducing oxidative stress, which is secondary to an imbalance between ACE and ACE2, might be the best way to prevent and treat COVID-19. ACE2 is inactivated when bound to a virus. This inactivation of ACE2 subsequently leads to an imbalance between the numbers of angiotensin II (ANGII) and angiotensin molecules. By binding to AT1R, ANGII activates NADPH oxidases, which transport an electron from NADPH to O2, producing O·-2, as well as downstream peroxynitrite, hydroxyl radical, and H2O2, which can be removed from the environment by GSH (an antioxidant molecule). Oxidant-antioxidant imbalances are not uncommon among SARS patients and are common to all inflammatory lung diseases and activate redox-sensitive transcription factors such as NF-κB. This activation is reversed by GSH. Oxidative stress is caused by an imbalance between the oxidative system in the body, which consists mainly of free radicals and reactive oxygen systems that neutralize these free radicals and can have several harmful effects. 8 Oxidative stress is involved in certain infections, especially those caused by RNA viruses, a family that also includes coronaviruses. In general, viral infections increase the production of free radicals and decrease the presence of antioxidants. 9 Disorders of redox homeostasis appear to be common to all COVID-19-related conditions, which are responsible for the accumulation of reactive oxygen species (ROS). Therefore, levels of glutathione (GSH; a key antioxidant in all tissues) and other antioxidants such as glutathione reductase can be critical to quenching the exacerbated inflammation that causes organ failure in COVID-19. Therefore, restoring antioxidant levels is vital when trying to protect the most vulnerable people from the severe symptoms of COVID-19. Reducing secondary oxidative stress to an imbalance between ACE and ACE2 may be the best way to prevent and treat Studies on the role of oxidative stress in the pathology of infection have focused on infections other than SARS-CoV2. In infections such as hepatitis B, oxidative stress can be caused by increased total lipid peroxidation and inadequate antioxidant response, which is strongly related to disease and viral load. 10 In sepsis, an overly inflammatory response to the invading pathogen is a greater pathophysiological challenge than the pathogen itself. In the systemic inflammatory response, both endothelial cells and neutrophils are activated to release free radicals. These oxidized On the other hand, the relationship between inflammation and oxidative stress is well established. 13 In a previous study, the clinical features of COVID-19 were examined in a group of patients in Shanghai. Compared to non-ICU patients, patients admitted to the ICU were found to have higher glutathione reductase than other patients (66.7 vs. 36.9). 14 In another study that investigated the relationship between antioxidant defense status, malondialdehyde (MDA), and viral load in patients with hepatitis C virus (HCV) infection, it was found that oxidative stress participates in the pathogenesis of HCV infections. Fifty patients whose HCV infections were The results showed that MAYV caused significant oxidative stress in HepG2-infected cells. This was demonstrated by an increase in MDA and carbonyl protein levels and a significant decrease in the ratio of reduced glutathione to oxidized glutathione (GSH/GSSG). 16 Inflammation is involved in COVID-19 pathology. In COVID-19 patients, the release of pro-inflammatory cytokines causes active inflammation, which damages the lungs. 17 The alteration of inflammatory markers in COVID-19 patients can be a good indicator to consider when finding these patients. Studies have shown a link between inflammatory markers and the severity of COVID-19. 18 Interleukin-10 (IL-10) is one of the cytokines that predicts the severity of COVID-19 disease. 19 The necessary information was given to the selected individuals via telephone conversations, and they were invited to Imam Khomeini Health Center of Abadan. In this center, the participants completed and signed the informed consent form. Comorbidities and COVID-19 symptoms were evaluated using a researcher-made questionnaire for the self-report of patients. Patients were then referred to a private health laboratory in Abadan for blood sampling. The day of referral to Imam Khomeini Health Center was considered the first day of the study for each participant. Clinical symptoms of positive-PCR outpatients were followed up on and recorded for 28 days in 1-week intervals by telephone contact. The study groups were as follows: 1) Negative-PCR: The non-COVID-19 group comprised patients whose COVID-19 disease was not confirmed by PCR. Also, the CT results of these people were checked if available-if the person's CT was positive despite the negative PCR test, the person was not included in the study. In addition to CT, the jobs of people whose PCR was negative were checked. If the person had a high-risk job (e.g., medical staff, bank staff), he/she was excluded from the study. The history of exposure and suspicious symptoms of individuals in this group were also accurately assessed through reporting from individuals to minimize the possibility of false results in the negative PCR test. People who reported a history of exposure or suspicious symptoms, such as NAGHASHPOUR ET AL. | 1459 fever, coughing, and headaches in the last 2 weeks were not included in the study despite the negative PCR test result. 2) Positive-PCR: These patients were infected individuals whose PCR tests were positive for SARS-CoV2. Fifty-two participants were included in each group. However, in each group, seven serum samples were not usable because they contained insufficient volumes required for biochemical analysis. In Imam Khomeini Health Center of Abadan, an expert colleague recorded participants' comorbidities using a researcher-made questionnaire for self-reporting. Hypertension, diabetes, cancer, liver disease, chronic lung disease, chronic neurological disease, chronic kidney disease, chronic heart disease, and AIDS/HIV were questioned. COVID-19 clinical signs were assessed in four categories as (1) General (fever, fatigue, night sweating, shivering, runny nose, and sore throat), (2) pulmonary (chest pain, dry cough, and breath shortness), (3) gastrointestinal (nausea, vomiting, anorexia, diarrhea, constipation, and blowing), and (4) neurologic (myalgia, ear pain, joint pain, taste/odor disorder, and headache). 21 Moreover, clinical symptoms of the positive-PCR group were followed for 28 days at weekly intervals. To measure the levels of glutathione reductase in serum, samples and standards were first prepared. Then, 50 μl of the sample/standard was added to the test tubes for each previously labeled sample/ standard. In the next step, 50 μl of R4 was added. Then, 1 ml of chromogen solution was added to the test tube. The resulting mixture was heated in a boiling water bath for 1 h. The tubes were then allowed to cool in an ice bath and then centrifuged for 10 min at 3000-4000 rpm. In the next step, 200 μl of the pink supernatant was removed by pipette. The supernatant was poured into a microplate, and the sample absorbance was read at 535 nm using an ELISA reader. To measure serum levels of IL-10, after preparing the reagents, samples, and standards, we added 40 μl of the sample, plus 10 μl of the interleukin 10 antibodies, to the respective wells. We then added 50 μl of the standards to the respective wells. Also, 50 μl of streptavidin-HRP was added to all wells. The wells were then incubated at 37°C for one hour. After that, washing was performed, and 100 μl of chromogen solution was added. The mixture was incubated for 10 min at 37°C. Then, 50 μl of stop solution was added, and the adsorption was read at 450 nm using an ELISA reader. Using standard concentrations and read absorptions, the standard curve was plotted, and then the concentration of interleukin 10 in each sample was calculated. Using the Kolmogorov-Smirnov test, the normality of the data was checked. The results were demonstrated as mean ± standard deviation (SD) for quantitative and number (percent) for qualitative vari- ables. An independent sample t-test was used to compare quantitative data, and the Chi-square was used to compare the qualitative data between the study groups. The generalized esti- The results of the comparison of comorbidities and clinical signs between positive and negative-PCR groups are presented in Table 1 . In the studied comorbidities, significant differences were not observed between positive and negative groups, which was expected due to the presence of PCR-positive outpatients in the early (asymptomatic/mild, moderate) stages of the disease. In line with our observations, Yang et al. 22 found that underlying diseases may be risk factors for severe patients compared with non-severe patients. Our results are also consistent with those of other studies showing that underlying diseases are associated with a poor prognosis and a higher chance of worsening disease and death. In the positive-PCR group, hypertension, diabetes, liver disease, chronic heart disease, and chronic kidney disease were the most common comorbidities (18.9%, 11.3%, 9.4%, 7.5%, and 5.7%, respectively). Yang et al., 22 in a systematic review and meta-analysis, also found that the most prevalent comorbidities in 1576 infected patients were hypertension and diabetes, which is in line with our results. Like us, Guan et al. 23 reported that the most prevalent comorbidity in their study population (1590 cases of COVID-19) was hypertension, followed by diabetes. We assessed and reported clinical symptoms in four categories. In the general category, we found a significant difference between negative and positive-PCR groups, except regarding the runny nose symptom. In the pulmonary category, there was a significant difference between the two groups except in terms of chest pain. Gastrointestinal symptoms were assessed only in the positive-PCR group. Diarrhea, nausea, blowing, constipation, and vomiting were the most common gastrointestinal symptoms (35.8%, 20.8%, 15.1%, 9.4%, and 5.7%, respectively). We also detected a significant difference in neurologic symptoms, except for ear pain, between negative and positive PCR groups. Odor disorder was not assessed in the negative-PCR group. Table 1 . We found significantly lower levels of GR in the positive-PCR group (p = 0.000). Also, the serum levels of IL-10 were significantly higher in the positive-PCR group (p = 0.000). A common denominator in all conditions associated with COVID-19 appears to be the impairment of redox homeostasis, which is responsible for ROS accumulation. So, the antioxidant system could be critical in extinguishing the exacerbated inflammation that triggers organ failure caused by COVID-19. GR is an enzyme that catalyzes the reduction of glutathione disulfide (GSSG) to the sulfhydryl form of glutathione (GSH), which is a critical molecule in resisting oxidative stress and maintaining the reducing environment of the cell. 24 Karkhanei et al. 25 Increased levels of inflammatory cytokines and excessive activation of T lymphocytes, macrophages, and endothelial cells called "cytokine storm" were observed in COVID-19 cases. Interferon-gamma (IFN-γ), interleukin 6 (IL-6), tumor necrosis factoralpha (TNF-a), IL-10, IL-1, IL-5, IL-8, IL-10, and granulocytemacrophage colony-stimulating factor (GM-CSF) were reported to be the main mediators behind cytokine storm. 4 Lu et al. 27 reported a unique feature of cytokine storms in COVID-19 patients (i.e., the dramatic elevation of IL-10), which supports the results obtained in our study. This elevation is thought to be a negative feedback mechanism to suppress inflammation. Inefficient viral clearance at any stage is a hallmark of COVID-19. Disease severity is associated with increases in peripheral blood cytokines, among which IL-10 increases particularly early and independently of patient age, which is not seen in active SARS-CoV infections. The known multi-faceted immune regulatory role of IL-10-both in protecting the lung from injury and in defense against infections, as well as its potential cellular sourceshould be considered. Although the absence of an IL-10 response in SARS is thought to contribute to early deterioration, it is expected that IL-10 protects the lungs from early immune-mediated damage and interferes with viral clearance in COVID-19. 28 Also, in experimental Rhesus Macaques, serum IL-10 levels were elevated about 16fold as early as on the first day after SARS-CoV-2 infection. 29 In contrast to COVID-19, blood levels of IL-10 in symptomatic SARS patients, including severe cases, did not differ from the blood of the control group. The lack of an increase in IL-10 in SARS-CoV infection has been suggested to contribute to early immunemediated lung damage 30 and, more recently, to a higher frequency of the fatal aggravation of lung injuries in SARS patients when compared to COVID-19 patients. 31 3.3 | Possible association between basal serum levels of estimated biomarkers and the progression of symptoms during the clinical course of the disease The relationships of serum levels of GR and IL-0 with the progression of symptoms during the clinical course of the disease are presented in Table 2 . In terms of the general, pulmonary, and gastrointestinal categories of symptoms, we did not see any relationships between any of the examined parameters and the chances of symptoms occurring. In the neurologic category, there was a significant relationship between serum levels of IL-10 and the chances of symptoms occurring over time. Thus, serum levels of IL-10 (OR = 0.914, p = 0.012) had a T A B L E 2 Odds ratio (OR) and 95% confidence interval (95% CI) estimated by GEE analysis with AR (1) model to determine the clinical symptoms' progression and the associations with serum levels of GR, and IL-10 among positive PCR outpatients decreasing effect on the outcomes and the chance of occurrence of neurological symptoms. In line with our observation, Zhao et al. 32 demonstrated that the early production of inhibitory mediators, including IL-10 and IL-1RA, were significantly associated with disease severity. They also reported that a combination of CCL5, IL-1 receptor antagonist (IL-1RA), and IL-10 at week one might predict the patient's outcomes. They enrolled a total of 71 patients with laboratory-confirmed COVID-19 and 18 healthy volunteers. 32 In the infected systems of the viral agents, there are significant changes to cellular homeostasis. These changes are caused mainly by high levels of oxidative stress biomarkers and depletion of the anti- Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv The COVID-19 cytokine storm; what we know so far Diagnosing COVID-19: the disease and tools for detection The impact of COVID-19 infection on the cytokine profile of pregnant women: a prospective case-control study Hosts and sources of endemic human coronaviruses Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives Mild versus severe COVID-19: laboratory markers COVID-19: can glutathione (GSH) help to reduce severe symptoms? COVID-19 infection and oxidative stress: an underexplored approach for prevention and treatment? Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection Serum total antioxidant capacity reflects severity of illness in patients with severe sepsis Markers of oxidative stress in erythrocytes and plasma during aging in humans Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection Clinical features of patients infected with the 2019 novel coronavirus (COVID-19 The relationship between viral load and malondialdehyde and antioxidant enzymes in patients with hepatitis C virus infection Implications of oxidative stress on viral pathogenesis Inflammatory markers in Covid-19 Patients: a systematic review and meta-analysis. medRxiv Association of inflammatory markers with the severity of COVID-19: a meta-analysis Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors IL-10: a multifunctional cytokine in viral infections Serum nutrient deficiencies in the patient with complex temporomandibular joint problems Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19 Evaluation of oxidative stress level: total antioxidant capacity, total oxidant status and glutathione activity in patients with COVID-19 Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: a cross-sectional comparative study in Jigawa, Northwestern Nigeria A potential role of interleukin 10 in COVID-19 pathogenesis Lung protection vs. infection resolution: interleukin 10 suspected of double-dealing in COVID-19 ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome Interleukin-10 aerosol reduces proinflammatory mediators in bronchoalveolar fluid of endotoxemic rat Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease Profiling serum levels of glutathione reductase and interleukin-10 in positive and negative-PCR COVID-19 outpatients: A comparative study from southwestern Iran The authors would like to express their deepest gratitude to all staff and supervisors of the Abadan University of Medical Sciences for their support of this study. This study was financially supported by the Abadan University of Medical Sciences (Grant no. 99T-888). The authors declare that there are no conflict of interests. Sahar Golabi contributed to conceptualization, project administration, methodology, and writing the original draft. Mahshid Naghashpour contributed to the methodology and writing the original draft. Maryam Adelipour, Hamid Ghiassian, Sara Mobarak, and Maghsud Piri contributed to the methodology, data collection, and investigation.Maryam Seyedtabib contributed to data analysis. Sahar Golabi contributed to funding acquisition, formal analysis, supervision, writing, review & editing. Data are available from the corresponding author upon reasonable request.